二价mRNA加强疫苗对奥密克戎变异株有效性的系统综述与荟萃分析
该系统综述与荟萃分析纳入28项研究、涉及55,393,303人,评估二价mRNA加强疫苗对奥密克戎相关感染和重症事件的绝对与相对有效性。结果显示,相比未接种及≥2剂或≥3剂原始单价疫苗,二价加强针对重症的保护更高,全年龄组相对有效性分别为57.6%和62.1%,≥60岁组为63.4%和60.7%。
要点
- 二价加强针对有症状或任何感染的全年龄组合并绝对有效性为53.5%(95%CI:-22.2-82.3%),对比未接种。
- 对比≥2剂和≥3剂原始单价疫苗,全年龄组相对有效性分别为30.8%(95%CI:22.5-38.2%)和28.4%(95%CI:10.2-42.9%)。
- 对重症事件,全年龄组对比未接种、≥2剂和≥3剂原始单价疫苗的有效性分别为72.9%、57.6%和62.1%。
核心结论
- 二价加强疫苗在各年龄组中对重症结局的保护优于原始单价加强疫苗,强调需提高疫苗覆盖率,尤其是脆弱老年亚群。
研究设计与样本
- 系统综述与荟萃分析,检索8个文献数据库,纳入2022年9月1日至2023年11月8日发表的评估SARS-CoV-2 BA.1型或BA.4/5型二价mRNA疫苗绝对或相对有效性的研究。
- 共纳入28项研究,涉及55,393,303人。
主要发现
- 全年龄组合并有症状或任何感染的绝对有效性为53.5%(95%CI:-22.2-82.3%),对比未接种;相对有效性为30.8%(95%CI:22.5-38.2%)对比≥2剂原始单价疫苗,28.4%(95%CI:10.2-42.9%)对比≥3剂原始单价疫苗。
- ≥60岁成人有症状或任何感染的有效性分别为22.5%(95%CI:16.8-39.8%)对比未接种、31.4%(95%CI:27.7-35.0%)对比≥2剂、30.6%(95%CI:-13.2-57.5%)对比≥3剂原始单价疫苗。
- 全年龄组针对重症事件的合并有效性分别为72.9%(95%CI:60.5-82.4%)对比未接种、57.6%(95%CI:42.4-68.8%)对比≥2剂、62.1%(95%CI:54.6-68.3%)对比≥3剂原始单价疫苗。
- ≥60岁成人针对重症事件的有效性分别为72.0%(95%CI:51.4-83.9%)对比未接种、63.4%(95%CI:41.0-77.3%)对比≥2剂、60.7%(95%CI:52.4-67.6%)对比≥3剂原始单价疫苗。
临床怎么用
- 原文结论强调需提高疫苗覆盖率,尤其是脆弱老年亚群,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A global shift to bivalent mRNA vaccines is ongoing to counterbalance the diminishing effectiveness of the original monovalent vaccines due to the evolution of SARS-CoV-2 variants, yet substantial variation in the bivalent vaccine effectiveness (VE) exists across studies and a complete picture is lacking. METHODS: We searched papers evaluating absolute or relative effectiveness of SARS-CoV-2 BA.1 type or BA.4/5 type bivalent mRNA vaccines on eight publication databases published from September 1st, 2022, to November 8th, 2023. Pooled VE against Omicron-associated infection and severe events (hospitalization and/or death) was estimated in reference to unvaccinated, ≥2 original monovalent doses, and ≥ 3 original monovalent doses. RESULTS: From 630 citations identified, 28 studies were included, involving 55,393,303 individuals. Bivalent boosters demonstrated higher effectiveness against symptomatic or any infection for all ages combined, with an absolute VE of 53.5 % (95 % CI: -22.2-82.3 %) when compared to unvaccinated and relative VE of 30.8 % (95 % CI: 22.5-38.2 %) and 28.4 % (95 % CI: 10.2-42.9 %) when compared to ≥ 2 and ≥ 3 original monovalent doses, respectively. The corresponding VE estimates for adults ≥ 60 years old were 22.5 % (95 % CI: 16.8-39.8 %), 31.4 % (95 % CI: 27.7-35.0 %), and 30.6 % (95 % CI: -13.2-57.5 %). Pooled bivalent VE estimates against severe events were higher, 72.9 % (95 % CI: 60.5-82.4 %), 57.6 % (95 % CI: 42.4-68.8 %), and 62.1 % (95 % CI: 54.6-68.3 %) for all ages, and 72.0 % (95 % CI: 51.4-83.9 %), 63.4 % (95 % CI: 41.0-77.3 %), and 60.7 % (95 % CI: 52.4-67.6 %) for adults ≥ 60 years old, compared to unvaccinated, ≥2 original monovalent doses, and ≥ 3 original monovalent doses, respectively. CONCLUSIONS: The bivalent boosters demonstrated superior protection against severe outcomes than the original monovalent boosters across age groups, highlighting the critical need for improving vaccine coverage, especially among the vulnerable older subpopulation.
引用
- Song S, Madewell ZJ, Liu M, et al. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants. Vaccine. 2024. PMID: 38653679. doi:10.1016/j.vaccine.2024.04.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。